Pink Sheet is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Zometa two-year data "approvable"

This article was originally published in Pharmaceutical Approvals Monthly

Executive Summary

Novartis' Zometa (zoledronic acid) sNDA to include two-year follow-up data on patients with bone metastases from advanced cancers is "approvable" Aug. 15, "pending future labeling discussions," the firm says. The long-term data comes from three pivotal trials, ranging in duration from nine to 12 months, that supported Zometa's February 2002 approval for multiple myeloma and bone metastases of solid tumors (1Pharmaceutical Approvals Monthly Nov. 1, 2002, p. 9). Novartis estimates that 500,000 patients worldwide have received Zometa...
Advertisement

Related Content

Topics

Advertisement
UsernamePublicRestriction

Register

PS002375

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel